Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
PHASE2CompletedINTERVENTIONAL
Enrollment
172
Participants
Timeline
Start Date
October 24, 2014
Primary Completion Date
April 22, 2016
Study Completion Date
June 18, 2021
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
BIOLOGICAL
pembrolizumab
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT02255097 - Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) | Biotech Hunter | Biotech Hunter